University of Texas Texas AM Investment Management Co. Purchases New Shares in Pfizer Inc. $PFE

University of Texas Texas AM Investment Management Co. acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel reports. The fund acquired 100,701 shares of the biopharmaceutical company’s stock, valued at approximately $2,507,000.

Several other institutional investors have also recently made changes to their positions in PFE. Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at about $1,830,986,000. Morgan Stanley grew its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. increased its stake in Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares during the last quarter. Finally, Capital World Investors lifted its position in shares of Pfizer by 51.5% during the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock worth $533,704,000 after buying an additional 7,287,194 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity drug berobenatide posted encouraging Phase 2b results, with favorable tolerability and proof-of-concept data that could strengthen the company’s late-stage pipeline. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: Pfizer has been upgraded by RBC Capital, reinforcing optimism around the stock’s valuation and income appeal. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Positive Sentiment: The CEO said Pfizer could eventually get back to high-single-digit growth, suggesting the business may be better positioned than some investors expect. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Multiple research and analyst roundups focused on Pfizer’s growth drivers, challenges, and recent stock performance, keeping the stock in the spotlight but without a major new catalyst. Top Research Reports for Pfizer & Newmont Corp.
• Neutral Sentiment: Pfizer was among the most searched stocks on Zacks, reflecting investor curiosity around what comes next for the name. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Coverage on Pfizer’s discounted valuation weighed the downside from fading COVID revenue and patent cliffs against upside from oncology, new products, and pipeline execution. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Barclays began coverage on Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.82.

Pfizer Stock Down 0.8%

Shares of NYSE PFE opened at $26.01 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market capitalization of $148.24 billion, a PE ratio of 19.86 and a beta of 0.34. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The business’s fifty day moving average price is $26.38 and its 200-day moving average price is $26.33.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.